IP-cure-B is a five-year project started in January 2020, coordinated by INSERM in France.
Hepatitis B virus (HBV) is a major global public health threat with over 257 million people worldwide.
Stimulating innate signaling and inhibiting viral replication in infected hepatocytes.
Perform a proof of concept clinical trial to evaluate novel immune modulators and their
combination to boost...
Improve the functional cure rate in CHB and provide opportunities for finite duration curing
Your Full Name